Aequus Pharmaceuticals Inc

Healthcare CA AQS

NoneCAD
0.00(0%)

Last update at 2026-05-14T21:00:15.724128Z

Day Range

LowHigh

52 Week Range

0.0050.005

LowHigh

Fundamentals

Previous Close -
Market Cap0.66M
VolumeNone
P/E Ratio-
Dividend Yield-%
EBITDA-2.37473M
Revenue TTM0.92M
Revenue Per Share TTM0.007
Gross Profit TTM 0.52M
Diluted EPS TTM-0.02

Overview
Financials
Peer Comparison
Reports
Stock Research & News
Profile

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Income before tax	-2.17766M	-2.96472M	-3.21004M	-1.80959M	-1.04536M
Minority interest	-	-	-	-	-
Net income	-2.17766M	-2.96472M	-3.21004M	-1.80959M	-1.04536M
Selling general administrative	2.33M	2.17M	2.98M	3.63M	2.96M
Selling and marketing expenses	-	0.36M	0.49M	-	-
Gross profit	0.33M	0.00550M	1.15M	2.69M	-
Reconciled depreciation	0.13M	0.14M	0.13M	0.13M	0.21M
Ebit	-	-2.82029M	-2.49804M	-1.60753M	-0.77980M
Ebitda	-	-2.68213M	-2.36821M	-1.22664M	-0.31480M
Depreciation and amortization	-	0.14M	0.13M	-	-
Non operating income net other	-	-	-	-	-
Operating income	-2.12720M	-2.82029M	-2.49804M	-1.36745M	-0.52610M
Other operating expenses	-	3.08M	3.88M	-	-
Interest expense	0.25M	0.15M	0.21M	0.45M	0.52M
Tax provision	-	-	-	-	-
Interest income	0.00490M	0.00413M	0.02M	0.01M	0.00453M
Net interest income	-0.24847M	-0.14105M	-0.18930M	-0.44166M	-0.51506M
Extraordinary items	-	-	-	-	-
Non recurring	-	-	-	-	-
Other items	-	-	-	-	-
Income tax expense	-	-0.00000M	-0.00000M	-	-
Total revenue	0.58M	0.25M	1.38M	2.71M	2.59M
Total operating expenses	2.71M	2.83M	3.64M	4.08M	3.12M
Cost of revenue	0.25M	0.25M	0.23M	0.03M	-
Total other income expense net	0.20M	-0.14443M	-0.71200M	-0.00048M	-0.00420M
Discontinued operations	-	-	-	-	-
Net income from continuing ops	-2.17766M	-2.96472M	-3.21004M	-1.80959M	-1.04536M
Net income applicable to common shares	-	-	-	-1.80959M	-1.04536M
Preferred stock and other adjustments	-	-	-	-	-

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Total assets	0.80M	1.09M	1.69M	4.35M	3.13M
Intangible assets	-	-	-	-	-
Earning assets	-	-	-	-	-
Other current assets	-	0.07M	0.20M	-	-
Total liab	7.26M	5.38M	3.07M	2.56M	2.56M
Total stockholder equity	-6.45499M	-4.29384M	-1.38004M	1.79M	0.57M
Deferred long term liab	-	-	-	-	-
Other current liab	-	0.04M	2.20M	-	-
Common stock	-	23.99M	23.99M	23.99M	21.17M
Capital stock	23.99M	23.99M	23.99M	23.99M	21.17M
Retained earnings	-34.86191M	-32.68425M	-29.71953M	-26.50948M	-24.69989M
Other liab	-	-	-	-	-
Good will	-	-	-	-	-
Other assets	-	0.00000M	-	0.51M	-
Cash	0.05M	0.17M	0.25M	2.39M	1.72M
Cash and equivalents	-	-	-	-	-
Total current liabilities	6.80M	4.80M	2.38M	2.46M	0.38M
Current deferred revenue	-	0.00000M	-	-	-
Net debt	5.98M	4.89M	0.53M	-	0.26M
Short term debt	-	4.48M	0.09M	-	-
Short long term debt	6.03M	4.37M	2.00M	1.93M	-
Short long term debt total	-	5.06M	0.78M	-	-
Other stockholder equity	-	-0.00000M	-	4.31M	4.10M
Property plant equipment	-	-	-	0.24M	0.37M
Total current assets	0.28M	0.44M	0.90M	3.59M	2.77M
Long term investments	-	-	-	-	-
Net tangible assets	-	-	-	1.79M	0.57M
Short term investments	-	0.04M	0.04M	-	-
Net receivables	0.05M	0.03M	0.31M	0.94M	0.78M
Long term debt	-	-	-	0.03M	1.98M
Inventory	0.04M	0.12M	0.09M	0.14M	0.12M
Accounts payable	0.54M	0.27M	0.09M	0.16M	0.16M
Total permanent equity	-	-	-	-	-
Noncontrolling interest in consolidated entity	-	-	-	-	-
Temporary equity redeemable noncontrolling interests	-	-	-	-	-
Accumulated other comprehensive income	-	4.40M	4.35M	-	-
Additional paid in capital	-	-	-	-	-
Common stock total equity	-	-	-	-	-
Preferred stock total equity	-	-	-	-	-
Retained earnings total equity	-	-	-	-	-
Treasury stock	-	-	-	-	-
Accumulated amortization	-	-	-	-	-
Non currrent assets other	-	-0.00000M	-	-	-
Deferred long term asset charges	-	-	-	-	-
Non current assets total	0.52M	0.65M	0.79M	0.76M	0.37M
Capital lease obligations	0.58M	0.69M	0.78M	0.23M	0.35M
Long term debt total	-	-	-	-	-

Breakdown	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Type	yearly	yearly	yearly	yearly	yearly
Date	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Investments	0.04M	0.00000M	0.00000M	-0.50796M	-0.01232M
Change to liabilities	-	-	-	0.14M	-0.09541M
Total cashflows from investing activities	-	-	-	-0.50796M	-0.01232M
Net borrowings	1.49M	2.21M	-0.18919M	-0.14751M	-0.10383M
Total cash from financing activities	1.49M	2.21M	-0.18919M	2.40M	2.05M
Change to operating activities	-	-	-	0.07M	-0.08519M
Net income	-2.17766M	-2.96472M	-3.21004M	-1.80959M	-1.04536M
Change in cash	-0.11995M	-0.07962M	-2.14173M	0.72M	1.23M
Begin period cash flow	0.17M	0.25M	2.39M	1.72M	0.48M
End period cash flow	0.05M	0.17M	0.25M	2.44M	1.72M
Total cash from operating activities	-1.65596M	-2.29399M	-1.95258M	-1.17221M	-0.80491M
Issuance of capital stock	-	-	0.00000M	2.55M	2.16M
Depreciation	0.13M	0.14M	0.13M	0.13M	0.21M
Other cashflows from investing activities	-	-	-	-	-
Dividends paid	-	-	-	-	-
Change to inventory	0.09M	-0.02992M	0.05M	-0.01650M	-0.11789M
Change to account receivables	-0.02663M	0.28M	0.62M	-0.16156M	-0.22322M
Sale purchase of stock	-	-	-	-	-
Other cashflows from financing activities	-	2.37M	-0.15119M	-0.00575M	-0.34458M
Change to netincome	-	-	-	0.48M	0.55M
Capital expenditures	0.00000M	0.00000M	0.00000M	0.00412M	0.01M
Change receivables	-	-	-	-	-
Cash flows other operating	-	-	-	-	-
Exchange rate changes	-	-	-	-	-
Cash and cash equivalents changes	-	-	-	-	-
Change in working capital	0.32M	0.42M	0.45M	0.03M	-0.52170M
Stock based compensation	0.02M	0.05M	0.04M	0.22M	0.30M
Other non cash items	0.06M	0.12M	0.37M	0.27M	0.25M
Free cash flow	-1.65596M	-2.29399M	-1.95258M	-1.17633M	-0.81722M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company	Change (CAD)	Price (CAD)	Trailing PE (x)	Forward PE (x)	Price Sales TTM (x)	Price to Book Value (x)	Enterprise Value to Revenue (x)	Enterprise Value to EBITDA (x)
AQS Aequus Pharmaceuticals Inc	- -%	-	-	-	0.72	24.39	34.48	-2.1936
RX Biosyent Inc.	0.05 0.36%	14.00	19.10	15.85	3.96	4.11	3.31	11.03
DB Decibel Cannabis Company Inc	- -%	0.12	-	8.67	0.67	1.20	0.99	17.75
ZYUS ZYUS Life Sciences Corporation	- -%	0.50	-	-	108.48	4.41	140.29	-4.258
LSL LSL Pharma Group Inc.	0.005 1.59%	0.32	20.75	-	1.88	1.89	2.85	10.19

Reports Covered

View All

Profile

Aequus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers ZIMED PF, a preservative-free bimatoprost prescription drug for the for the reduction of elevated interocular pressure in patients with open angle glaucoma or ocular hypertension. It also develops REV-0100, which is in pre-clinical trial for the treatment of stargardt disease. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Aequus Pharmaceuticals Inc

200 Granville Street, Vancouver, BC, Canada, V6C 1S4

604 336 7906
https://www.aequuspharma.ca

Key Executives

Name	Title	Year Born
Mr. Douglas Glen Janzen	Chairman, CEO & Pres	1969
Ms. Ann Fehr CGA, CPA	CFO & Corp. Sec.	1969
Mr. Stuart Fowler	Strategic Commercial Advisor & Independent Director	NA
Mr. Grant Larsen	Chief Commercial Officer	NA
Mr. Douglas Glen Janzen	Chairman, CEO & President	1969
Ms. Ann Fehr CGA, CPA	CFO & Corporate Secretary	1969
Mr. Rabin Ramanjooloo	Chief Operating Officer	NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.